You Can Now Generate ChatGPT Images by Texting a 1-800 Number on WhatsApp
The feature, announced by OpenAI on Monday in an X post, allows anyone with a WhatsApp account to text that phone number and make a request for an AI-generated image using a plain-language prompt.
In CNET's test, ChatGPT's 1-800 hotline was able to create an old-school corded telephone image with the ChatGPT logo on it in about two minutes. The 1-800 number also accepts other ChatGPT requests that aren't for images. If you don't have a ChatGPT account linked to your WhatsApp, you're limited to one image request per day.
In April, ChatGPT announced it was opening up its image-generation feature to everyone, which created a surge of traffic for the AI tool. The service competes with image generators from other companies including Meta and Google.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, Revolution Medicines and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a clinical collaboration to evaluate combinations of Revolution Medicines' investigational RAS(-ON) inhibitors with Summit Therapeutics' ivonescimab in multiple solid tumor settings. The collaboration will assess the safety and efficacy of these combinations in RAS mutant non-small cell lung cancer/NSCLC, pancreatic ductal adenocarcinoma/PDAC, and colorectal cancer/CRC. Under the agreement, Summit Therapeutics will supply ivonescimab for clinical research, while Revolution Medicines will serve as the study sponsor. Both companies will retain commercial rights to their respective compounds. A researcher poring over test results, illustrating the breakthrough potential of biotechnology. The agreement is mutually non-exclusive, allowing each company to pursue additional partnerships. Revolution Medicines will contribute 3 of its clinical-stage RAS(-ON) inhibitors to the collaboration: daraxonrasib (RMC-6236), which is a multi-selective inhibitor; zoldonrasib (RMC-9805), which is a G12D-selective inhibitor; and elironrasib (RMC-6291), which is a G12C-selective inhibitor. Revolution Medicines Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company. While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Associated Press
26 minutes ago
- Associated Press
DentScribe Launches GPS - AI-Powered "Guided Production System" Transforming Dental Practice Operations and Revenue Optimization
SAN JOSE, Calif., July 6, 2025 /PRNewswire/ -- today announced the launch of DentScribe GPS (Guided Production System), a groundbreaking addition to its AI-powered dental software suite, building upon the successful DentScribe CoPilot. DentScribe GPS provides dental practices with a comprehensive, practice-wide view of patient care, production opportunities, and actionable insights drawn directly from the dentist's AI-generated SOAP notes. Unlike traditional dashboards based on static diagnostic imaging (e.g., x-rays), DentScribe GPS leverages the dentist's own professional assessments captured in SOAP notes, reflecting the 'ground truth' of clinical needs and treatment plans. This real-time AI analysis ensures precise identification of high-value production opportunities, urgent patient care interventions, and daily operational priorities. DentScribe GPS delivers its insights through a user-friendly, tablet-first interface specifically optimized for morning huddles and daily planning sessions. Dental teams gain immediate visibility into critical alerts, planned production, patient follow-ups, and comprehensive practice performance metrics. DentScribe GPS visually categorizes opportunities by urgency, provider, discipline, and financial value, empowering teams to prioritize effectively. Dr. Vinni K. Singh, DDS, founder and CEO of remarked, 'DentScribe GPS changes everything about our morning huddles. We now start each day knowing exactly where to focus our efforts to maximize both patient care and practice profitability. By harnessing AI-driven insights directly from our SOAP notes, we are identifying care opportunities and revenue streams that diagnostic tools alone simply cannot see.' Early adopters report significant practice improvements, including: DentScribe GPS includes a unique Daily Brief (DentScribe GPS Intelligence), which provides a concise summary of critical daily priorities, revenue optimization strategies, and team productivity goals. Dental teams can quickly review key insights and make informed decisions at the start of each day. DentScribe GPS is now available nationwide, building upon the success of DentScribe CoPilot and further establishing DentScribe as the market leader in AI-driven dental practice management. To see DentScribe GPS in action and experience immediate, measurable results in your dental practice, schedule a demo today at Media Contact: [email protected] View original content to download multimedia: SOURCE DentScribe
